Pemetrexed for the Treatment of Chordoma

Status Completed

Clinical Trial Summary

The purpose of this study is to test the safety and tolerability of pemetrexed administered to people with chordoma. Other purposes of this study are to: - find out side effects (good and bad) of pemetrexed; - learn more about how pemetrexed might affect the growth of cancer cells; - evaluate tumor characteristics by collecting tumor tissue samples if available; - look at biomarkers (biochemical features that can be used to measure the progress of disease or the effects of a drug) in blood and cerebrospinal fluid if available.

Clinical Trial Description

This is a prospective, open-label, single-arm pilot feasibility study of pemetrexed for the treatment of adult patients with chordoma. All patients providing informed consent will be screened for eligibility. Eligible patients will receive pemetrexed by intravenous infusion on Day 1 of each 21-day treatment cycle, pre-medications (folic acid, vitamin B12, and dexamethasone), and ibuprofen if needed. Patients will continue dosing of pemetrexed until disease progression, unacceptable toxicity, withdrawal of consent, or treating physician determines it is in their best interest to stop. All patients will have regular evaluations for assessment of safety parameters and anti-tumor activity as detailed in the study flow chart. ;

Study Design

Related Conditions & MeSH terms

Chordoma

Clinical Trial Details

NCT number	NCT03955042
Study type	Interventional
Source	Saint John's Cancer Institute
Contact
Status	Completed
Phase	Phase 1
Start date	September 6, 2019
Completion date	January 18, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01347307` - Stereotactic Body Radiotherapy for Spine Tumors	N/A
Active, not recruiting	`NCT00496119` - Proton Beam Therapy for Chordoma Patients	Phase 2
Recruiting	`NCT06029218` - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy	N/A
Completed	`NCT03595228` - BN Brachyury and Radiation in Chordoma	Phase 2
Recruiting	`NCT06140732` - Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma	Phase 2
Active, not recruiting	`NCT01175109` - Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma	Phase 1
Completed	`NCT00150072` - Efficacy and Safety of Imatinib in Chordoma	Phase 2
Terminated	`NCT00003926` - Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors	Phase 1
Recruiting	`NCT05041127` - Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma	Phase 2
Recruiting	`NCT05861245` - Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base	N/A
Completed	`NCT00464620` - Trial of Dasatinib in Advanced Sarcomas	Phase 2
Completed	`NCT02383498` - QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma	Phase 2
Recruiting	`NCT03242382` - Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.	Phase 2
Completed	`NCT02520128` - A Study of IMRT in Primary Bone and Soft Tissue Sarcoma	N/A
Recruiting	`NCT01567046` - Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas	N/A
Recruiting	`NCT02986516` - Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease	N/A
Completed	`NCT00919269` - Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Active, not recruiting	`NCT02989636` - Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma	Phase 1
Active, not recruiting	`NCT03083678` - Afatinib in Locally Advanced and Metastatic Chordoma	Phase 2
Completed	`NCT00713037` - Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas	N/A